share_log
Breakings ·  Jun 14 14:00
Cabaletta Bio Reports Positive Initial Clinical Data From Phase 1/2 Reset-Myositis™ and Reset-Sle™ Trials of Caba-201
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment